Marjolijn Duijm‐de Carpentier

Fasting mimicking diet as an adjunct to neoadjuvant chemotherapy for breast cancer in the multicentre randomized phase 2 DIRECT trial

Stefanie de Groot, Rieneke T. Lugtenberg, Danielle Cohen et al. · Nature Communications · 2020 · 335 citations · Full text

Medicine, Nutritional Sciences, Oncology +17

Optimal Duration of Extended Adjuvant Endocrine Therapy for Early Breast Cancer; Results of the IDEAL Trial (BOOG 2006-05)

Erik J. Blok, Judith R. Kroep, Elma Meershoek‐Klein Kranenbarg et al. · JNCI Journal of the National Cancer Institute · 2017 · 201 citations · Full text

Medicine, Oncology, Pharmacology +15

Breast Cancer Index Predicts Extended Endocrine Benefit to Individualize Selection of Patients with HR+ Early-stage Breast Cancer for 10 Years of Endocrine Therapy

Iris Noordhoek, Kai Treuner, Hein Putter et al. · Clinical Cancer Research · 2020 · 133 citations · Full text

Medicine, Endocrinology, Oncology +17

Quality of life and illness perceptions in patients with breast cancer using a fasting mimicking diet as an adjunct to neoadjuvant chemotherapy in the phase 2 DIRECT (BOOG 2013–14) trial

Rieneke T. Lugtenberg, Stefanie de Groot, Maarten J. Fischer et al. · Breast Cancer Research and Treatment · 2020 · 62 citations · Full text

Medicine, Nutrition, Oncology +17

Overestimation of Late Distant Recurrences in High-Risk Patients With ER-Positive Breast Cancer: Validity and Accuracy of the CTS5 Risk Score in the TEAM and IDEAL Trials

Iris Noordhoek, Erik J. Blok, Elma Meershoek‐Klein Kranenbarg et al. · Journal of Clinical Oncology · 2020 · 43 citations · Full text

Medicine, Oncology, Breast Oncology +15